Shopping Cart
- Remove All
- Your shopping cart is currently empty
NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | 44 € | In Stock | |
10 mg | 76 € | In Stock | |
25 mg | 154 € | In Stock | |
50 mg | 234 € | In Stock | |
100 mg | 353 € | In Stock | |
500 mg | 825 € | In Stock |
Description | NFATc1-IN-1 (also known as compound A04) is a highly effective inhibitor of osteoclast formation induced by RANKL, with an IC50 of 1.57 μM. It exerts its anti-osteoclastogenic effects by attenuating the RANKL-induced nuclear translocation of NFATc1. Due to its remarkable properties, NFATc1-IN-1 holds significant potential for advancing research related to osteoclastic diseases [1]. |
Targets&IC50 | Osteoclast:1.57 μM |
In vitro | NFATc1-IN-1 (0、0.5、1.0、1.5、2.0、2.5 μM, 4 days) exhibits potent inhibitory activities on osteoclast formation and function, which eventually translates into decreased bone resorption while showing no cytotoxic effects towards osteoclast precursor cells at concentrations of as high as 2.5 μM.[1] NFATc1-IN-1 (1.5-2.5 μM, 24 h) blocks NFATc1 nuclear translocation and decreases the level of NFATc1.[1] |
Molecular Weight | 375.11 |
Formula | C13H8F2INO2 |
Cas No. | 1912422-56-0 |
Smiles | C(NC1=C(F)C=C(I)C=C1)(=O)C2=C(O)C=CC(F)=C2 |
Storage | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 112.5 mg/mL (299.9 mM ), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.